Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of Safety and Durable Immunogenicity of Melanoma Vaccination, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma

Trial Profile

Evaluation of Safety and Durable Immunogenicity of Melanoma Vaccination, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Peptide vaccines (Primary) ; Peptide vaccines (Primary) ; Varlilumab (Primary) ; Cyclophosphamide; Montanide ISA-51; Montanide ISA-51; Poly ICLC; Poly ICLC
  • Indications Malignant melanoma
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms Mel-65
  • Most Recent Events

    • 08 Aug 2019 Status changed from suspended to recruiting.
    • 06 Jun 2019 Status changed from recruiting to suspended.
    • 13 Nov 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top